MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
0.4643
-0.0017
-0.36%
Pre Market: 0.4600 -0.0043 -0.93% 08:20 06/11 EDT
OPEN
0.4460
PREV CLOSE
0.4660
HIGH
0.4920
LOW
0.4460
VOLUME
6.95K
TURNOVER
0
52 WEEK HIGH
7.19
52 WEEK LOW
0.4200
MARKET CAP
13.00M
P/E (TTM)
-0.1439
1D
5D
1M
3M
1Y
5Y
1D
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
TipRanks · 1d ago
Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
Benzinga · 2d ago
JASPER THERAPEUTICS - ON JUNE 3, 2026, CO RECEIVES NASDAQ NOTICE FOR MINIMUM BID PRICE NON-COMPLIANCE - SEC FILING
Reuters · 2d ago
Jasper Therapeutics gets Nasdaq notice after shares trade below $1 bid-price minimum
PUBT · 2d ago
Weekly Report: what happened at JSPR last week (0601-0605)?
Weekly Report · 3d ago
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate
Benzinga · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (JSPR) and Corbus Pharmaceuticals (CRBP)
TipRanks · 06/01 18:00
BUZZ-U.S. STOCKS ON THE MOVE-Grail, Kohl, Virgin Galactic
Reuters · 06/01 17:40
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.